{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T01:54:15Z","timestamp":1791942855660,"version":"4.3.4"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,1,13]],"date-time":"2024-01-13T00:00:00Z","timestamp":1705104000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,1,13]],"date-time":"2024-01-13T00:00:00Z","timestamp":1705104000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Actelion Pharmaceuticals Ltd, a Janssen Pharmaceutical Company of Johnson & Johnson"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1007\/s12325-023-02730-8","type":"journal-article","created":{"date-parts":[[2024,1,13]],"date-time":"2024-01-13T03:02:24Z","timestamp":1705114944000},"page":"1103-1119","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Real-World Management of Patients with Pulmonary Arterial Hypertension: Insights from EXPOSURE"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-9438-539X","authenticated-orcid":false,"given":"Audrey","family":"Muller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Escribano-Subias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catarina C.","family":"Fernandes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Fontana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias J.","family":"Lange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"S\u00f6derberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Gaine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,13]]},"reference":[{"key":"2730_CR1","doi-asserted-by":"publisher","first-page":"3618","DOI":"10.1093\/eurheartj\/ehac237","volume":"43","author":"M Humbert","year":"2022","unstructured":"Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, Brida M, et al. 2022 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2022;43:3618\u2013731. https:\/\/doi.org\/10.1093\/eurheartj\/ehac237.","journal-title":"Eur Heart J"},{"key":"2730_CR2","doi-asserted-by":"publisher","first-page":"2200879","DOI":"10.1183\/13993003.00879-2022","volume":"61","author":"M Humbert","year":"2023","unstructured":"Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, Brida M, et al. 2022 ESC\/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J. 2023;61:2200879. https:\/\/doi.org\/10.1183\/13993003.00879-2022.","journal-title":"Eur Respir J"},{"key":"2730_CR3","doi-asserted-by":"publisher","first-page":"2102024","DOI":"10.1183\/13993003.02024-2021","volume":"59","author":"MM Hoeper","year":"2022","unstructured":"Hoeper MM, Pausch C, Gr\u00fcnig E, Staehler G, Huscher D, Pittrow D, et al. Temporal trends in pulmonary arterial hypertension: results from the COMPERA registry. Eur Respir J. 2022;59:2102024. https:\/\/doi.org\/10.1183\/13993003.02024-2021.","journal-title":"Eur Respir J"},{"key":"2730_CR4","doi-asserted-by":"publisher","first-page":"2102419","DOI":"10.1183\/13993003.02419-2021","volume":"59","author":"A Boucly","year":"2022","unstructured":"Boucly A, Weatherald J, Savale L, de Groote P, Cottin V, Pr\u00e9vot G, et al. External validation of a refined four-stratum risk assessment score from the French pulmonary hypertension registry. Eur Respir J. 2022;59:2102419. https:\/\/doi.org\/10.1183\/13993003.02419-2021.","journal-title":"Eur Respir J"},{"key":"2730_CR5","unstructured":"Swedish Pulmonary arterial hypertension registry (SPAHR). Annual Report 2022. https:\/\/www.ucr.uu.se\/spahr\/arsrapporter\/arsrapport-spahr-2022\/viewdocument\/163. Accessed Mar 2023."},{"key":"2730_CR6","doi-asserted-by":"publisher","DOI":"10.1002\/pul2.12150","volume":"12","author":"VV McLaughlin","year":"2022","unstructured":"McLaughlin VV, Channick R, Kim NH, Frantz RP, McConnell J, Melendres-Groves L, et al. Safety of macitentan for the treatment of pulmonary hypertension: real-world experience from the OPsumit\u00ae USers Registry (OPUS) and OPsumit\u00ae Historical USers cohort (OrPHeUS). Pulm Circ. 2022;12: e12150. https:\/\/doi.org\/10.1002\/pul2.12150.","journal-title":"Pulm Circ"},{"key":"2730_CR7","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1016\/j.healun.2020.09.011","volume":"39","author":"MM Hoeper","year":"2020","unstructured":"Hoeper MM, Pausch C, Gr\u00fcnig E, Klose H, Staehler G, Huscher D, et al. Idiopathic pulmonary arterial hypertension phenotypes determined by cluster analysis from the COMPERA registry. J Heart Lung Transplant. 2020;39:1435\u201344. https:\/\/doi.org\/10.1016\/j.healun.2020.09.011.","journal-title":"J Heart Lung Transplant"},{"key":"2730_CR8","doi-asserted-by":"publisher","first-page":"1700740","DOI":"10.1183\/13993003.00740-2017","volume":"50","author":"MM Hoeper","year":"2017","unstructured":"Hoeper MM, Kramer T, Pan Z, Eichstaedt CA, Spiesshoefer J, Benjamin N, et al. Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model. Eur Respir J. 2017;50:1700740. https:\/\/doi.org\/10.1183\/13993003.00740-2017.","journal-title":"Eur Respir J"},{"key":"2730_CR9","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1002\/pds.3891","volume":"17","author":"International Society for Pharmacoepidemiology","year":"2008","unstructured":"International Society for Pharmacoepidemiology. Guidelines for good pharmacoepidemiology practices (GPP). Pharmacoepidemiol Drug Saf. 2008;17:200\u20138. https:\/\/doi.org\/10.1002\/pds.3891.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2730_CR10","unstructured":"The European Network of Centres for Pharmacoepidemiology and Pharmacovigilance. Guide on Methodological Standards in Pharmacoepidemiology (Revision 10). EMA\/95098\/2010."},{"key":"2730_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/2045894018780521","volume":"8","author":"A Skride","year":"2018","unstructured":"Skride A, Sablinskis K, Lejnieks A, Rudzitis A, Lang I. Characteristics and survival data from Latvian pulmonary hypertension registry: comparison of prospective pulmonary hypertension registries in Europe. Pulm Circ. 2018;8:1\u20139. https:\/\/doi.org\/10.1177\/2045894018780521.","journal-title":"Pulm Circ"},{"key":"2730_CR12","doi-asserted-by":"publisher","DOI":"10.1002\/pul2.12001","volume":"12","author":"P Appenzeller","year":"2022","unstructured":"Appenzeller P, Lichtblau M, Berlier C, Aubert J-D, Azzola A, Fellrath J-M, et al. Disease characteristics and clinical outcome over two decades from the Swiss pulmonary hypertension registry. Pulm Circ. 2022;12: e12001. https:\/\/doi.org\/10.1002\/pul2.12001.","journal-title":"Pulm Circ"},{"key":"2730_CR13","doi-asserted-by":"publisher","first-page":"173","DOI":"10.3390\/jcm9010173","volume":"9","author":"G Kope\u0107","year":"2020","unstructured":"Kope\u0107 G, Kurzyna M, Mroczek E, Chrzanowski \u0141, Mularek-Kubzdela T, Skoczylas I, et al. Characterization of Patients with Pulmonary Arterial Hypertension: data from the Polish Registry of Pulmonary Hypertension (BNP-PL). J Clin Med. 2020;9:173. https:\/\/doi.org\/10.3390\/jcm9010173.","journal-title":"J Clin Med"},{"key":"2730_CR14","unstructured":"NHS Digital. National Audit of Pulmonary Hypertension. 13th Annual Report. https:\/\/files.digital.nhs.uk\/36\/B8B717\/NAPH%2013AR%20-%20Main%20Report%20v1.0.pdf. Accessed Jul 2023."},{"key":"2730_CR15","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1378\/chest.15-0300","volume":"148","author":"HW Farber","year":"2015","unstructured":"Farber HW, Miller DP, Poms AD, Badesch DB, Frost AE, Muros-Le Rouzic E, et al. Five-year outcomes of patients enrolled in the REVEAL Registry. Chest. 2015;148:1043\u201354. https:\/\/doi.org\/10.1378\/chest.15-0300.","journal-title":"Chest"},{"key":"2730_CR16","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.121.024969","volume":"11","author":"KY Chang","year":"2022","unstructured":"Chang KY, Duval S, Badesch DB, Bull TM, Chakinala MM, de Marco T, et al. Mortality in pulmonary arterial hypertension in the modern era: early insights from the pulmonary hypertension association registry. J Am Heart Assoc. 2022;11: e024969. https:\/\/doi.org\/10.1161\/JAHA.121.024969.","journal-title":"J Am Heart Assoc"},{"key":"2730_CR17","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.3390\/jcm9051456","volume":"9","author":"H Kaemmerer","year":"2020","unstructured":"Kaemmerer H, Gorenflo M, Huscher D, Pittrow D, Apitz C, Baumgartner H, et al. Pulmonary hypertension in adults with congenital heart disease: real-world data from the International COMPERA-CHD Registry. J Clin Med. 2020;9:1456. https:\/\/doi.org\/10.3390\/jcm9051456.","journal-title":"J Clin Med"},{"key":"2730_CR18","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/j.ijcard.2015.02.031","volume":"184","author":"R Alonso-Gonzalez","year":"2015","unstructured":"Alonso-Gonzalez R, Lopez-Guarch CJ, Subirana-Domenech MT, Ruiz JM, Gonzalez IO, Cubero JS, et al. Pulmonary hypertension and congenital heart disease: an insight from the REHAP National Registry. Int J Cardiol. 2015;184:717\u201323. https:\/\/doi.org\/10.1016\/j.ijcard.2015.02.031.","journal-title":"Int J Cardiol"},{"key":"2730_CR19","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1183\/09031936.00101211","volume":"40","author":"P Escribano-Subias","year":"2012","unstructured":"Escribano-Subias P, Blanco I, Lopez-Meseguer M, Lopez-Guarch CJ, Roman A, Morales P, et al. Survival in pulmonary hypertension in Spain: insights from the Spanish registry. Eur Respir J. 2012;40:596\u2013603. https:\/\/doi.org\/10.1183\/09031936.00101211.","journal-title":"Eur Respir J"},{"key":"2730_CR20","doi-asserted-by":"publisher","first-page":"4175","DOI":"10.1093\/eurheartj\/ehx257","volume":"39","author":"D Kylhammar","year":"2017","unstructured":"Kylhammar D, Kjellstrom B, Hjalmarsson C, Jansson K, Nisell M, Soderberg S, et al. A comprehensive risk stratification at early follow-up determines prognosis in pulmonary arterial hypertension. Eur Heart J. 2017;39:4175\u201381. https:\/\/doi.org\/10.1093\/eurheartj\/ehx257.","journal-title":"Eur Heart J"},{"key":"2730_CR21","doi-asserted-by":"publisher","first-page":"2102311","DOI":"10.1183\/13993003.02311-2021","volume":"60","author":"MM Hoeper","year":"2022","unstructured":"Hoeper MM, Pausch C, Olsson KM, Huscher D, Pittrow D, Gr\u00fcnig E, et al. COMPERA 2.0: a refined 4-strata risk assessment model for pulmonary arterial hypertension. Eur Respir J. 2022;60:2102311. https:\/\/doi.org\/10.1183\/13993003.02311-2021.","journal-title":"Eur Respir J"},{"key":"2730_CR22","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1080\/14017431.2016.1185532","volume":"50","author":"G R\u00e5degran","year":"2016","unstructured":"R\u00e5degran G, Kjellstr\u00f6m B, Ekmehag B, Larsen F, Rundqvist B, Blomquist SB, et al. Characteristics and survival of adult Swedish PAH and CTEPH patients 2000\u20132014. Scand Cardiovasc J. 2016;50:243\u201350. https:\/\/doi.org\/10.1080\/14017431.2016.1185532.","journal-title":"Scand Cardiovasc J"},{"key":"2730_CR23","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1093\/eurheartj\/ehv317","volume":"37","author":"N Gali\u00e8","year":"2016","unstructured":"Gali\u00e8 N, Humbert M, Vachi\u00e9ry JL, Gibbs S, Lang I, Torbicki A, et al. 2015 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: the Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2016;37:67\u2013119. https:\/\/doi.org\/10.1093\/eurheartj\/ehv317.","journal-title":"Eur Heart J"},{"key":"2730_CR24","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1183\/13993003.01032-2015","volume":"46","author":"N Gali\u00e8","year":"2015","unstructured":"Gali\u00e8 N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, et al. 2015 ESC\/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: the Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Respir J. 2015;46:903\u201375. https:\/\/doi.org\/10.1183\/13993003.01032-2015.","journal-title":"Eur Respir J"},{"key":"2730_CR25","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1183\/09031936.00057010","volume":"36","author":"M Humbert","year":"2010","unstructured":"Humbert M, Sitbon O, Ya\u00efci A, Montani D, O\u2019Callaghan DS, Jais X, et al. Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension. Eur Respir J. 2010;36:549\u201355. https:\/\/doi.org\/10.1183\/09031936.00057010.","journal-title":"Eur Respir J"},{"key":"2730_CR26","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1183\/09031936.00094112","volume":"40","author":"DP Miller","year":"2012","unstructured":"Miller DP, Gomberg-Maitland M, Humbert M. Survivor bias and risk assessment. Eur Respir J. 2012;40:530\u20132. https:\/\/doi.org\/10.1183\/09031936.00094112.","journal-title":"Eur Respir J"},{"key":"2730_CR27","doi-asserted-by":"publisher","first-page":"175346662199504","DOI":"10.1177\/1753466621995040","volume":"15","author":"F Exposto","year":"2021","unstructured":"Exposto F, Hermans R, Nordgren \u00c5, Taylor L, Sikander Rehman S, Ogley R, et al. Burden of pulmonary arterial hypertension in England: retrospective HES database analysis. Ther Adv Respir Dis. 2021;15:1753466621995040. https:\/\/doi.org\/10.1177\/1753466621995040.","journal-title":"Ther Adv Respir Dis"},{"key":"2730_CR28","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.ijcard.2020.02.034","volume":"306","author":"F Exposto","year":"2020","unstructured":"Exposto F, Petric\u0103 N, Davies E, Beaudet A. Identification of a pulmonary arterial hypertension (PAH) patient cohort and study of its burden of illness in Programme de M\u00e9dicalisation des Syst\u00e8mes d\u2019information (PMSI). Int J Cardiol. 2020;306:175\u201380. https:\/\/doi.org\/10.1016\/j.ijcard.2020.02.034.","journal-title":"Int J Cardiol"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-023-02730-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-023-02730-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-023-02730-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,20]],"date-time":"2024-02-20T18:14:22Z","timestamp":1708452862000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-023-02730-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,13]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["2730"],"URL":"https:\/\/doi.org\/10.1007\/s12325-023-02730-8","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,13]]},"assertion":[{"value":"2 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Audrey Muller is an employee of Janssen Pharmaceutical Companies of Johnson & Johnson and has Johnson & Johnson shares. Pilar Escribano-Subias has received payment or honoraria for lectures, presentations, speaker\u2019s bureaus, manuscript writing or educational events from Janssen Pharmaceutical Companies of Johnson & Johnson, MSD, Ferrer and AOT, has received support from Janssen Pharmaceutical Companies of Johnson & Johnson and MSD for attending meetings and\/or travel and has participated on a Data Safety Monitoring Board or Advisory Board for Janssen Pharmaceutical Companies of Johnson & Johnson, MSD, Ferrer, Gossamer and AOT. Catarina C Fernandes is an employee of Janssen Pharmaceutical Companies of Johnson & Johnson. Martina Fontana is an employee of Janssen Pharmaceutical Companies of Johnson & Johnson. Tobias J Lange has received speaker fees and\/or consultancy fees and\/or financial and non-financial support for participation in scientific events from Acceleron Pharma, AstraZeneca, Bayer, B\u00f6hringer Ingelheim, Ferrer, Gossamer Bio, Janssen Pharmaceutical Companies of Johnson & Johnson, MSD, Orphacare and Pfizer. Stefan S\u00f6derberg has received speaker and consultancy fees, and financial support for participation in scientific events from Janssen Pharmaceutical Companies of Johnson & Johnson. Sean Gaine has had relations, such as funding, with the following subjects that have commercial interests in the pharmaceutical and medical field: Aerovate Therapeutics, Acceleron, Altavant, Bayer, Gossamer Bio, Janssen Pharmaceutical Companies of Johnson & Johnson, MSD and United Therapeutics.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki, the International Society for Pharmacoepidemiology (ISPE) Guidelines for Good Pharmacoepidemiology Practices (GPP) and in accordance with the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP) Guide on Methodological Standards in Pharmacoepidemiology. The protocol was approved by the Institutional Review Board or Independent Ethics Committee at each study site (and at the national level in Sweden). Written informed consent was obtained from each patient for accessing and processing anonymised patient data and their use in scientific research.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}